Quick Answer
CervoMed Inc. reported R&D Expense of $21.82 million for fiscal year 2025.
CervoMed Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $21.82M | +16.1% |
| 2024 | $18.80M | +122.8% |
| 2023 | $8.44M | +531.4% |
| 2022 | $1.34M | -84.3% |
| 2021 | $8.50M | -9.8% |
| 2020 | $9.43M | +42.4% |
| 2019 | $6.62M | +15.1% |
| 2018 | $5.75M | +13.0% |
| 2017 | $5.09M | -29.8% |
| 2016 | $7.25M | +87.1% |
| 2015 | $3.88M | +35.5% |
| 2014 | $2.86M | +734.2% |
| 2013 | $342.9K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.04M | +17.9% | +18.2% |
| June 30, 2025 | $5.11M | +35.4% | +5.6% |
| March 31, 2025 | $4.84M | +71.9% | -5.6% |
| September 30, 2024 | $5.13M | +186.1% | +35.9% |
| June 30, 2024 | $3.77M | +92.6% | +34.0% |
| March 31, 2024 | $2.81M | +53.5% | +57.1% |
| September 30, 2023 | $1.79M | +442.0% | -8.5% |
| June 30, 2023 | $1.96M | -7.1% | +6.8% |
- CervoMed Inc. showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, CervoMed Inc.’s r&d expense has grown by 6262.2% (from $342.9 thousand to $21.82 million).
- The most recent figure is from CervoMed Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: